Rivaroxaban (Xarelto, BAY59-7939)

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Arthroplasty, Replacement, Hip

Conditions

Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee

Trial Timeline

Oct 1, 2011 → Jul 1, 2014

NCT ID

NCT01444586

About Rivaroxaban (Xarelto, BAY59-7939)

Rivaroxaban (Xarelto, BAY59-7939) is a pre-clinical stage product being developed by Bayer for Arthroplasty, Replacement, Hip. The current trial status is completed. This product is registered under clinical trial identifier NCT01444586. Target conditions include Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06193863	Pre-clinical	Active	Jun 18, 2024	Dec 31, 2026	Prevention of Venous Thromboembolism
NCT04923139	Pre-clinical	Completed	Jan 24, 2022	Dec 31, 2022	Treatment of Venous Thromboembolism
NCT04356989	Pre-clinical	Completed	May 13, 2020	Jan 16, 2023	Non-valvular Atrial Fibrillation (NVAF)
NCT04174859	Pre-clinical	Completed	Dec 10, 2019	Dec 12, 2022	Non-valvular Atrial Fibrillation
NCT03455439	Pre-clinical	Completed	Mar 16, 2018	Jan 11, 2022	Heart Failure
NCT03284762	Pre-clinical	Completed	Sep 11, 2017	Nov 20, 2019	Atrial Fibrillation
NCT03214172	Pre-clinical	Completed	Jul 15, 2017	Sep 15, 2017	Venous Thromboembolism
NCT02975453	Pre-clinical	Completed	Dec 5, 2016	Aug 26, 2020	Atrial Fibrillation
NCT03242278	Pre-clinical	Completed	Feb 12, 2016	Mar 1, 2016	Atrial Fibrillation
NCT02564718	Phase 1/2	Completed	Nov 19, 2015	Dec 18, 2017	Thromboembolism
NCT02558465	Pre-clinical	Completed	Nov 13, 2015	May 31, 2021	Venous Thromboembolism
NCT02309411	Phase 2	Completed	Jan 15, 2015	Apr 5, 2017	Venous Thromboembolism
NCT02262676	Pre-clinical	Completed	Oct 1, 2014	May 1, 2015	Atrial Fibrillation
NCT01523418	Pre-clinical	Withdrawn	Oct 1, 2014	Nov 1, 2016	Prophylaxis, Thromboembolism, Venous
NCT01839357	Phase 3	Completed	Aug 1, 2013	Dec 1, 2014	Atrial Fibrillation
NCT01855100	Pre-clinical	Completed	Jul 1, 2013	Dec 1, 2014	Venous Thrombosis
NCT01855139	Pre-clinical	Completed	Jul 1, 2013	Dec 1, 2014	Atrial Fibrillation
NCT01853800	Phase 1	Completed	May 1, 2013	Aug 1, 2013	Biological Availability
NCT01805544	Pre-clinical	Completed	May 1, 2013	Jun 1, 2015	Venous Thrombosis
NCT01805531	Pre-clinical	Completed	Apr 1, 2013	Mar 1, 2015	Atrial Fibrillation

Competing Products

9 competing products in Arthroplasty, Replacement, Hip

See all competitors

Product	Company	Stage	Hype Score
DU-176b	Daiichi Sankyo	Phase 2	52
YM150 + Warfarin	Astellas Pharma	Phase 2	52
Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503)	Johnson & Johnson	Phase 3	77
Zoledronic acid 5mg	Novartis	Approved	85
Denosumab	Amgen	Phase 2	51
JNJ-70033093 25 mg + JNJ-70033093 50 mg + JNJ-70033093 100 mg + JNJ-70033093 200 mg + Placebo + Enoxaparin 40 mg	Bristol Myers Squibb	Phase 2	51
Enoxaparin sodium	Sanofi	Phase 3	76
48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics	Sanofi	Pre-clinical	22
Enoxaparin + Apixaban + BAY1213790	Bayer	Phase 2	49

Other Products from Bayer

TelmisartanApproved

Clotrimazole vaginal tablet + FluconazoleApproved

Levitra (Vardenafil, BAY38-9456)Approved

Avelox (Moxifloxacin, BAY12-8039) + Amoxicillin clavulanic acidApproved

Rivaroxaban 20 MG + WarfarinApproved